In addition, by using the currently approved JAK inhibitors (JAKis), such as ruxolitinib (RUX) or fedratinib (FED), hemoglobin (Hb) reduction is an expected early on‐target effect, with grade 3/4 anemia occurring in 38–45% of cases [2]. Here, GSTM1 is linked to anemia.